2014 Q1 Form 10-Q Financial Statement

#000114420414025736 Filed on April 29, 2014

View on sec.gov

Income Statement

Concept 2014 Q1 2013 Q1
Revenue $15.58M $22.88M
YoY Change -31.88% 54.01%
Cost Of Revenue $13.78M $13.72M
YoY Change 0.49% 54.34%
Gross Profit $1.802M $9.162M
YoY Change -80.33% 53.52%
Gross Profit Margin 11.56% 40.05%
Selling, General & Admin $1.335M $1.757M
YoY Change -24.02% 0.4%
% of Gross Profit 74.08% 19.18%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization $205.0K $203.0K
YoY Change 0.99% 56.15%
% of Gross Profit 11.38% 2.22%
Operating Expenses $1.335M $1.757M
YoY Change -24.02% 0.4%
Operating Profit $467.0K $7.405M
YoY Change -93.69% 75.56%
Interest Expense $209.0K -$197.0K
YoY Change -206.09% -215.2%
% of Operating Profit 44.75% -2.66%
Other Income/Expense, Net
YoY Change
Pretax Income $258.0K $7.208M
YoY Change -96.42% 78.11%
Income Tax $98.00K $2.739M
% Of Pretax Income 37.98% 38.0%
Net Earnings $160.0K $4.469M
YoY Change -96.42% 78.12%
Net Earnings / Revenue 1.03% 19.53%
Basic Earnings Per Share $0.01 $0.18
Diluted Earnings Per Share $0.01 $0.17
COMMON SHARES
Basic Shares Outstanding 25.09M shares 24.33M shares
Diluted Shares Outstanding 26.85M shares 26.75M shares

Balance Sheet

Concept 2014 Q1 2013 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $2.500M $1.400M
YoY Change 78.57% 1300.0%
Cash & Equivalents $2.489M $1.437M
Short-Term Investments
Other Short-Term Assets $3.300M $2.400M
YoY Change 37.5% 50.0%
Inventory $26.10M $51.50M
Prepaid Expenses
Receivables $10.22M $6.500M
Other Receivables $2.700M $0.00
Total Short-Term Assets $44.83M $61.90M
YoY Change -27.57% 127.01%
LONG-TERM ASSETS
Property, Plant & Equipment $4.417M $4.700M
YoY Change -6.02% 34.98%
Goodwill
YoY Change
Intangibles $51.00K
YoY Change
Long-Term Investments $400.0K $1.200M
YoY Change -66.67%
Other Assets $93.00K $3.700M
YoY Change -97.49% 3089.66%
Total Long-Term Assets $10.25M $9.700M
YoY Change 5.67% 131.45%
TOTAL ASSETS
Total Short-Term Assets $44.83M $61.90M
Total Long-Term Assets $10.25M $9.700M
Total Assets $55.08M $71.60M
YoY Change -23.07% 127.6%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $7.600M $9.300M
YoY Change -18.28% 106.67%
Accrued Expenses $400.0K $400.0K
YoY Change 0.0% 0.0%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $14.20M $17.20M
YoY Change -17.44% 258.33%
Total Short-Term Liabilities $22.21M $29.00M
YoY Change -23.42% 196.98%
LONG-TERM LIABILITIES
Long-Term Debt $4.597M $4.800M
YoY Change -4.23% 3210.34%
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $4.597M $4.800M
YoY Change -4.23% 3210.34%
TOTAL LIABILITIES
Total Short-Term Liabilities $22.21M $29.00M
Total Long-Term Liabilities $4.597M $4.800M
Total Liabilities $26.80M $33.80M
YoY Change -20.7% 241.07%
SHAREHOLDERS EQUITY
Retained Earnings -$16.95M
YoY Change
Common Stock $251.0K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $28.28M $37.80M
YoY Change
Total Liabilities & Shareholders Equity $55.08M $71.60M
YoY Change -23.07% 127.6%

Cashflow Statement

Concept 2014 Q1 2013 Q1
OPERATING ACTIVITIES
Net Income $160.0K $4.469M
YoY Change -96.42% 78.12%
Depreciation, Depletion And Amortization $205.0K $203.0K
YoY Change 0.99% 56.15%
Cash From Operating Activities $3.059M -$7.335M
YoY Change -141.7% 244.37%
INVESTING ACTIVITIES
Capital Expenditures $80.00K $173.0K
YoY Change -53.76% 8.13%
Acquisitions
YoY Change
Other Investing Activities $20.00K -$70.00K
YoY Change -128.57%
Cash From Investing Activities -$64.00K -$245.0K
YoY Change -73.88% 41.62%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $24.00K $607.0K
YoY Change -96.05%
Debt Paid & Issued, Net $77.00K $84.00K
YoY Change -8.33% -72.09%
Cash From Financing Activities -$1.175M $5.026M
YoY Change -123.38% -433.51%
NET CHANGE
Cash From Operating Activities $3.059M -$7.335M
Cash From Investing Activities -$64.00K -$245.0K
Cash From Financing Activities -$1.175M $5.026M
Net Change In Cash $1.820M -$2.554M
YoY Change -171.26% -32.97%
FREE CASH FLOW
Cash From Operating Activities $3.059M -$7.335M
Capital Expenditures $80.00K $173.0K
Free Cash Flow $2.979M -$7.508M
YoY Change -139.68% 227.86%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2013Q4 us-gaap Common Stock Value
CommonStockValue
251000 USD
CY2013Q1 us-gaap Net Income Loss
NetIncomeLoss
4469000 USD
CY2014Q1 us-gaap Net Income Loss
NetIncomeLoss
160000 USD
CY2014Q1 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: bold 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">Credit risk</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">Financial instruments, which potentially subject the Company to concentrations of credit risk, consist principally of temporary cash investments and trade accounts receivable. The Company maintains its temporary cash investments in highly-rated financial institutions and, at times, the balances exceed FDIC insurance coverage. The Company's trade accounts receivables are primarily due from companies throughout the United States. The Company reviews each customer's credit history before extending credit.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">The Company establishes an allowance for doubtful accounts based on factors associated with the credit risk of specific accounts, historical trends, and other information. The carrying value of the Company&#8217;s accounts receivable is reduced by the established allowance for doubtful accounts. The allowance for doubtful accounts includes any accounts receivable balances that are determined to be uncollectible, along with a general reserve for the remaining accounts receivable balances. The Company adjusts its reserves based on factors that affect the collectability of the accounts receivable balances.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"> &#160;&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">For the three month period ended March 31, 2014, three customers each accounted for 10% or more of the Company&#8217;s revenues and, in the aggregate these <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> three</font> customers accounted for <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 44</font>% of the Company&#8217;s revenues. At March 31, 2014, there were $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">6,337,000</font> in outstanding receivables from these customers.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">For the three month period ended March 31, 2013, two customers each accounted for 10% or more of the Company&#8217;s revenues and, in the aggregate these <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> two</font> customers accounted for <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 44</font>% of the Company&#8217;s revenues. At March 31, 2013, there were $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">2,923,000</font> in outstanding receivables from these customers.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">The loss of a principal customer or a decline in the economic prospects of and/or a reduction in purchases of the Company's products or services by any such customer could have a material adverse effect on the Company's operating results and financial position.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2014Q1 us-gaap Use Of Estimates
UseOfEstimates
<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: bold 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">Estimates and risks</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">The preparation of financial statements in conformity with generally accepted accounting principles in the United States requires management to make estimates and assumptions that affect reported amounts of certain assets and liabilities, the disclosure of contingent assets and liabilities, and the results of operations during the reporting period. Actual results could differ from these estimates.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">The Company utilizes both internal and external sources to evaluate potential current and future liabilities for various commitments and contingencies. In the event that the assumptions or conditions change in the future, the estimates could differ from the original estimates.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">Several of the Company's accounting policies involve significant judgments, uncertainties and estimations. The Company bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities. Actual results may differ from these estimates under different assumptions or conditions. To the extent that actual results differ from management's judgments and estimates, there could be a material adverse effect on the Company. On a continuous basis, the Company evaluates its estimates, including, but not limited to, those estimates related to its allowance for doubtful accounts, inventory reserves, and valuation allowance for the deferred tax assets relating to its NOLs and commitments and contingencies. With respect to accounts receivable, the Company estimates the necessary allowance for doubtful accounts based on both historical and anticipated trends of payment history and the ability of the customer to fulfill its obligations. For inventory, the Company evaluates both current and anticipated sales prices of its products to determine if a write down of inventory to net realizable value is necessary. In determining the Company&#8217;s valuation allowance for its deferred tax assets, the Company assesses its ability to generate taxable income in the future.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"> &#160;&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">The Company participates in an industry that is highly regulated, and changes in the regulations affecting our business could affect our operating results. Currently the Company purchases virgin, hydrochlorofluorocarbon (&#8220;HCFC&#8221;) and hydrofluorocarbon (&#8220;HFC&#8221;) refrigerants and reclaimable, primarily HCFC and chlorofluorocarbon (&#8220;CFC&#8221;), refrigerants from suppliers and its customers. Effective January 1, 1996, the Clean Air Act (the &#8220;Act&#8221;) prohibited the production of virgin CFC refrigerants and limited the production of virgin HCFC refrigerants. Effective January 2004, the Act further limited the production of virgin HCFC refrigerants and federal regulations were enacted which established production and consumption allowances for HCFC refrigerants and which imposed limitations on the importation of certain virgin HCFC refrigerants. Under the Act, production of certain virgin HCFC refrigerants is scheduled to be phased out during the period 2010 through 2020, and production of all virgin HCFC refrigerants is scheduled to be phased out by 2030. In December 2009, the Environmental Protection Agency (&#8220;EPA&#8221;) published a final rule (the &#8220;2009 Rule&#8221;) which limited the total pounds of virgin HCFC refrigerants that could be produced and imported for the years 2010 through 2014 to levels which, based upon the EPA&#8217;s estimates, would require as much as 20% of the service demand for existing equipment to be met by reclaimed or recycled HCFC refrigerants. As a result of litigation, the 2009 Rule was vacated, and in April 2013, the EPA issued a final rule (the &#8220;April 2013 Rule&#8221;) providing for further reductions in the production and importation of HCFC refrigerants in the years 2013 and 2014 when compared to the reductions originally established in the 2009 Rule. In December 2013, a proposed rule was issued by the EPA to address production and consumption allowances for HCFC refrigerants for the years 2015 through 2019. In the proposed rule, the EPA discusses several alternatives for the phase down of HCFC-22 during the years 2015 through 2019, and identifies a preferred approach that would implement a linear draw down for the production or importation of HCFC-22 that would start at <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">30</font> million pounds in 2015 and reduce by approximately <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">6</font> million pounds each year and end at zero in 2020. A final rule to address production and consumption allowances for the years 2015 through 2019 has not yet been issued by the EPA. The Company expects that a final rule establishing the actual number of pounds for the years 2015 through 2019 will be issued late in 2014.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">To the extent that the Company is unable to source sufficient quantities of refrigerants or is unable to obtain refrigerants on commercially reasonable terms or experiences a decline in demand and/or price for refrigerants sold by the Company, the Company could realize reductions in revenue from refrigerant sales, which could have a material adverse effect on its operating results and its financial position.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">The Company is subject to various legal proceedings. The Company assesses the merit and potential liability associated with each of these proceedings. In addition, the Company estimates potential liability, if any, related to these matters. To the extent that these estimates are not accurate, or circumstances change in the future, the Company could realize liabilities, which could have a material adverse effect on its operating results and its financial position.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2014Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
2489000 USD
CY2013Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
669000 USD
CY2014Q1 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
10221000 USD
CY2013Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
3706000 USD
CY2014Q1 us-gaap Income Taxes Receivable
IncomeTaxesReceivable
2709000 USD
CY2013Q4 us-gaap Income Taxes Receivable
IncomeTaxesReceivable
2709000 USD
CY2014Q1 us-gaap Inventory Net
InventoryNet
26104000 USD
CY2013Q4 us-gaap Inventory Net
InventoryNet
33967000 USD
CY2014Q1 us-gaap Deferred Tax Assets Net Current
DeferredTaxAssetsNetCurrent
207000 USD
CY2013Q4 us-gaap Deferred Tax Assets Net Current
DeferredTaxAssetsNetCurrent
207000 USD
CY2014Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3103000 USD
CY2013Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
608000 USD
CY2014Q1 us-gaap Assets Current
AssetsCurrent
44833000 USD
CY2013Q4 us-gaap Assets Current
AssetsCurrent
41866000 USD
CY2014Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
4417000 USD
CY2013Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
4536000 USD
CY2014Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
93000 USD
CY2013Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
106000 USD
CY2014Q1 us-gaap Deferred Tax Assets Net Noncurrent
DeferredTaxAssetsNetNoncurrent
5265000 USD
CY2013Q4 us-gaap Deferred Tax Assets Net Noncurrent
DeferredTaxAssetsNetNoncurrent
5363000 USD
CY2014Q1 us-gaap Investments In And Advances To Affiliates At Fair Value
InvestmentsInAndAdvancesToAffiliatesAtFairValue
424000 USD
CY2013Q4 us-gaap Investments In And Advances To Affiliates At Fair Value
InvestmentsInAndAdvancesToAffiliatesAtFairValue
440000 USD
CY2014Q1 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
51000 USD
CY2013Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
57000 USD
CY2014Q1 us-gaap Assets
Assets
55083000 USD
CY2013Q4 us-gaap Assets
Assets
52368000 USD
CY2014Q1 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
7577000 USD
CY2013Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
3955000 USD
CY2014Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
388000 USD
CY2013Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
289000 USD
CY2014Q1 us-gaap Debt Current
DebtCurrent
14242000 USD
CY2013Q4 us-gaap Debt Current
DebtCurrent
15367000 USD
CY2014Q1 us-gaap Liabilities Current
LiabilitiesCurrent
22207000 USD
CY2013Q4 us-gaap Liabilities Current
LiabilitiesCurrent
19611000 USD
CY2014Q1 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
4597000 USD
CY2013Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
4671000 USD
CY2014Q1 us-gaap Liabilities
Liabilities
26804000 USD
CY2013Q4 us-gaap Liabilities
Liabilities
24282000 USD
CY2014Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2013Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2014Q1 us-gaap Common Stock Value
CommonStockValue
251000 USD
CY2014Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
44977000 USD
CY2013Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
44944000 USD
CY2014Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-16949000 USD
CY2013Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-17109000 USD
CY2014Q1 us-gaap Stockholders Equity
StockholdersEquity
28279000 USD
CY2013Q4 us-gaap Stockholders Equity
StockholdersEquity
28086000 USD
CY2014Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
55083000 USD
CY2013Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
52368000 USD
CY2014Q1 dei Entity Incorporation Date Of Incorporation
EntityIncorporationDateOfIncorporation
1991-01-11
CY2013Q1 hdsn Customers Accounting For Ten Percent Or More Of Net Revenue
CustomersAccountingForTenPercentOrMoreOfNetRevenue
2 pure
CY2014Q1 hdsn Customers Accounting For Ten Percent Or More Of Net Revenue
CustomersAccountingForTenPercentOrMoreOfNetRevenue
3 pure
CY2013Q1 hdsn Entity Wide Revenue Major Customer Percentage Of Revenue
EntityWideRevenueMajorCustomerPercentageOfRevenue
0.44 pure
CY2014Q1 hdsn Entity Wide Revenue Major Customer Percentage Of Revenue
EntityWideRevenueMajorCustomerPercentageOfRevenue
0.44 pure
CY2014Q1 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
5472000 USD
CY2013Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
5570000 USD
CY2014Q1 us-gaap Operating Loss Carryforwards Limitations On Use
OperatingLossCarryforwardsLimitationsOnUse
Approximately $10,600,000 of the Companys $16,000,000 of NOLs are subject to annual limitations of $1,300,000.
CY2013Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
50000 shares
CY2014Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
50000 shares
CY2013Q1 us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
21810000 USD
CY2014Q1 us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
14172000 USD
CY2013Q1 us-gaap Sales Revenue Services Net
SalesRevenueServicesNet
1067000 USD
CY2014Q1 us-gaap Sales Revenue Services Net
SalesRevenueServicesNet
1412000 USD
CY2013Q1 us-gaap Revenues
Revenues
22877000 USD
CY2014Q1 us-gaap Revenues
Revenues
15584000 USD
CY2013Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
24334966 shares
CY2014Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
25090386 shares
CY2013Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
26751714 shares
CY2014Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
26851678 shares
CY2014Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2013Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2014Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
50000000 shares
CY2013Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
50000000 shares
CY2014Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
25090386 shares
CY2013Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
25070386 shares
CY2014Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
25090386 shares
CY2013Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
25070386 shares
CY2013Q1 us-gaap Line Of Credit Facility Maximum Borrowing Capacity
LineOfCreditFacilityMaximumBorrowingCapacity
40000000 USD
CY2012Q2 us-gaap Line Of Credit Facility Maximum Borrowing Capacity
LineOfCreditFacilityMaximumBorrowingCapacity
27000000 USD
CY2014Q1 us-gaap Deferred Finance Costs Net
DeferredFinanceCostsNet
125000 USD
CY2014Q1 us-gaap Line Of Credit Facility Amount Outstanding
LineOfCreditFacilityAmountOutstanding
17958000 USD
CY2014Q1 us-gaap Line Of Credit Facility Current Borrowing Capacity
LineOfCreditFacilityCurrentBorrowingCapacity
7612000 USD
CY2014Q1 us-gaap Line Of Credit Facility Interest Rate At Period End
LineOfCreditFacilityInterestRateAtPeriodEnd
0.030 pure
CY2014Q1 us-gaap Line Of Credit Facility Interest Rate Description
LineOfCreditFacilityInterestRateDescription
Interest charges with respect to loans are computed on the actual principal amount of loans outstanding during the month at a rate per annum equal to (A) with respect to domestic rate loans, the sum of (i) a rate per annum equal to the higher of (1) the base commercial lending rate of PNC, (2) the federal funds open rate plus .5% and (3) the daily LIBOR plus 1%, plus (ii) .5% and (B) with respect to Eurodollar rate loans, the sum of the Eurodollar rate plus 2.75%.
CY2013Q1 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
13715000 USD
CY2014Q1 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
13782000 USD
CY2013Q1 us-gaap Gross Profit
GrossProfit
9162000 USD
CY2014Q1 us-gaap Gross Profit
GrossProfit
1802000 USD
CY2013Q1 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
823000 USD
CY2014Q1 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
650000 USD
CY2013Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
934000 USD
CY2014Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
685000 USD
CY2014Q1 hdsn Production And Importation Permission From Government Agency
ProductionAndImportationPermissionFromGovernmentAgency
51000000 lb
CY2014Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-7863000 USD
CY2013Q1 us-gaap Operating Expenses
OperatingExpenses
1757000 USD
CY2014Q1 us-gaap Operating Expenses
OperatingExpenses
1335000 USD
CY2013Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
7405000 USD
CY2014Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
467000 USD
CY2013Q1 us-gaap Interest Expense
InterestExpense
-197000 USD
CY2014Q1 us-gaap Interest Expense
InterestExpense
-209000 USD
CY2013Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
7208000 USD
CY2014Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
258000 USD
CY2013Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
2739000 USD
CY2014Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
98000 USD
CY2013Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.18
CY2014Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.01
CY2013Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.17
CY2014Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.01
CY2013Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
33000 USD
CY2014Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
9000 USD
CY2014Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
5500000 shares
CY2014Q1 us-gaap Deferred Compensation Arrangement With Individual Common Stock Reserved For Future Issuance
DeferredCompensationArrangementWithIndividualCommonStockReservedForFutureIssuance
2521733 shares
CY2013Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
50000 shares
CY2014Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
0 shares
CY2014Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
74000 USD
CY2014Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
2816000 USD
CY2014Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
3783977 USD
CY2014Q1 hdsn Share Based Compensation Arrangement By Share Based Payment Award Options Vested In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodTotalIntrinsicValue
0 USD
CY2014Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
52000 USD
CY2013Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0 pure
CY2014Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0 pure
CY2013Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0085 pure
CY2014Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0 pure
CY2013Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.76 pure
CY2014Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0 pure
CY2013Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y
CY2014Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P0Y
CY2013Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
203000 USD
CY2014Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
205000 USD
CY2013Q1 hdsn Amortization Of Deferred Financing Costs
AmortizationOfDeferredFinancingCosts
21000 USD
CY2014Q1 hdsn Amortization Of Deferred Financing Costs
AmortizationOfDeferredFinancingCosts
25000 USD
CY2013Q1 us-gaap Share Based Compensation
ShareBasedCompensation
33000 USD
CY2014Q1 us-gaap Share Based Compensation
ShareBasedCompensation
9000 USD
CY2013Q1 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
497000 USD
CY2014Q1 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
98000 USD
CY2013Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
4561000 USD
CY2014Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
6515000 USD
CY2013Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
11367000 USD
CY2013Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1482000 USD
CY2014Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
2507000 USD
CY2013Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
4852000 USD
CY2014Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
3721000 USD
CY2014Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
25090386 shares
CY2014Q1 dei Entity Registrant Name
EntityRegistrantName
HUDSON TECHNOLOGIES INC /NY
CY2014Q1 dei Entity Central Index Key
EntityCentralIndexKey
0000925528
CY2013Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-7335000 USD
CY2014Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
3059000 USD
CY2013Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
173000 USD
CY2014Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
80000 USD
CY2013Q1 us-gaap Investments In And Advances To Affiliates At Fair Value Period Increase Decrease
InvestmentsInAndAdvancesToAffiliatesAtFairValuePeriodIncreaseDecrease
-72000 USD
CY2014Q1 us-gaap Investments In And Advances To Affiliates At Fair Value Period Increase Decrease
InvestmentsInAndAdvancesToAffiliatesAtFairValuePeriodIncreaseDecrease
16000 USD
CY2013Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-245000 USD
CY2014Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-64000 USD
CY2013Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
607000 USD
CY2014Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
24000 USD
CY2013Q1 us-gaap Proceeds From Repayments Of Short Term Debt
ProceedsFromRepaymentsOfShortTermDebt
4503000 USD
CY2014Q1 us-gaap Proceeds From Repayments Of Short Term Debt
ProceedsFromRepaymentsOfShortTermDebt
-1122000 USD
CY2013Q1 us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
84000 USD
CY2014Q1 us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
77000 USD
CY2013Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
5026000 USD
CY2014Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-1175000 USD
CY2013Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-2554000 USD
CY2014Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
1820000 USD
CY2012Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
3991000 USD
CY2013Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1437000 USD
CY2013Q1 us-gaap Interest Paid
InterestPaid
176000 USD
CY2014Q1 us-gaap Interest Paid
InterestPaid
184000 USD
CY2014Q1 dei Document Type
DocumentType
10-Q
CY2014Q1 dei Amendment Flag
AmendmentFlag
false
CY2014Q1 dei Document Period End Date
DocumentPeriodEndDate
2014-03-31
CY2014Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2014
CY2014Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2014Q1 dei Trading Symbol
TradingSymbol
HDSN
CY2014Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2014Q1 dei Entity Filer Category
EntityFilerCategory
Smaller Reporting Company
CY2013Q1 hdsn Production And Importation Permission From Government Agency
ProductionAndImportationPermissionFromGovernmentAgency
63000000 lb

Files In Submission

Name View Source Status
0001144204-14-025736-index-headers.html Edgar Link pending
0001144204-14-025736-index.html Edgar Link pending
0001144204-14-025736.txt Edgar Link pending
0001144204-14-025736-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xls Edgar Link pending
Financial_Report.xlsx Edgar Link pending
hdsn-20140331.xml Edgar Link completed
hdsn-20140331.xsd Edgar Link pending
hdsn-20140331_cal.xml Edgar Link unprocessable
hdsn-20140331_def.xml Edgar Link unprocessable
hdsn-20140331_lab.xml Edgar Link unprocessable
hdsn-20140331_pre.xml Edgar Link unprocessable
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
v375382_10q.htm Edgar Link pending
v375382_ex31-1.htm Edgar Link pending
v375382_ex31-2.htm Edgar Link pending
v375382_ex32-1.htm Edgar Link pending
v375382_ex32-2.htm Edgar Link pending